Welcome to our dedicated page for Modular Med SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Modular Medical, Inc. (Nasdaq: MODD) files a range of reports and disclosures with the U.S. Securities and Exchange Commission (SEC) that document its activities as a development-stage medical device company focused on insulin delivery technology. This page aggregates those SEC filings and pairs them with AI-powered summaries to help readers understand the key points in each document.
For Modular Medical, current reports on Form 8-K are especially relevant. The company has used 8-K filings to describe material definitive agreements for underwritten public offerings of common stock and accompanying warrants, warrant inducement arrangements, and related gross proceeds. These filings also outline terms such as exercise prices, warrant durations, over-allotment options, and underwriter compensation. Other 8-Ks disclose Nasdaq notices regarding the company’s compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, including the time periods granted to regain compliance.
Registration statements on Form S-3 and other referenced registration statements are important for understanding how Modular Medical registers shares underlying warrants and other securities issued in its financings. Filings also confirm the company’s incorporation in Nevada and its status as a development-stage medical device company, as well as providing context for its capital structure.
On this page, AI-generated overviews highlight the main elements of each filing, such as new financing transactions, warrant terms, listing compliance developments, and references to the company’s insulin delivery technology focus. Users can quickly identify which documents address topics like public offerings, private placements, or Nasdaq communications, while still having access to the full text of the official SEC filings for detailed review.
Modular Medical, Inc. filed a shelf registration to offer up to $150,000,000 of securities to be issued from time to time, including common stock, preferred stock, debt securities, warrants and units, with specific offerings to be described in prospectus supplements. The company also established a sales agreement with Maxim Group LLC permitting at-the-market sales of up to $100,000,000 of common stock.
The prospectus discloses recent financing activity including a March 2026 registered direct offering that raised approximately $12.0 million, an April 2026 registered direct offering that raised approximately $3.375 million, a December 2025 public offering that raised approximately $4.7 million (plus a $0.7 million overallotment), a secured $350,000 credit note from the CEO, a 1-for-30 reverse stock split effective March 31, 2026, and FDA clearance received April 9, 2026 for the Pivot product with commercialization planned in the quarter ending June 30, 2026.
Modular Medical, Inc. entered into a Placement Agency Agreement for a registered direct offering of 750,000 shares of common stock at $4.50 per share, for expected gross proceeds of about $3.375 million before fees and expenses.
Maxim Group LLC will act as sole placement agent, earning a 7% cash fee on gross proceeds and expense reimbursement up to $75,000. The offering is made under an effective Form S-3 shelf registration and is expected to close on or about April 21, 2026, subject to customary conditions.
Company directors and executive officers agreed to 90-day lock-up restrictions, and the Company agreed to limit additional equity issuances for 45 days after closing, subject to specified exceptions.
Modular Medical, Inc. is offering 750,000 shares of common stock at $4.50 per share. The prospectus supplement states the offering price was negotiated with the placement agent and investors and delivery is expected on or about April 21, 2026.
The company expects net proceeds of approximately $2.9 million, which it intends to use for working capital, capital expenditures and general corporate purposes. The filing discloses substantial doubt about the company’s ability to continue as a going concern without additional financing and notes pivot product FDA clearance and a planned commercial launch.
Modular Medical, Inc. has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. Nasdaq notified the company after its common stock maintained a closing bid above the $1.00 minimum for 10 consecutive trading days through April 14, 2026.
With compliance restored under Nasdaq Listing Rule 5550(a)(2), Nasdaq considers the matter closed, meaning the company’s common stock can continue trading on the Nasdaq Capital Market under the symbol MODD without an active bid-price deficiency issue.
Modular Medical, Inc. director and ten percent owner C. Frank Morgan received fully vested options to purchase an additional 312 shares of common stock as compensation. The awards consist of options for 62 shares and 250 shares, each with an exercise price of $4.55 per share, granted under the company’s Outside Director Compensation Plan.
Modular Medical, Inc. director Ellen O'Connor Vos received a grant of options to purchase 250 shares of common stock. The options have an exercise price of $4.55 per share, were fully vested and exercisable on the March 31, 2026 grant date, and expire on March 31, 2036. After this award, she beneficially owns 250 options of this class of derivative security.
Modular Medical, Inc. director Jeff D. Goldberg received an option grant for 250 shares of common stock on March 31, 2026. The option has an exercise price of $4.55 per share, was granted under the company’s Outside Director Compensation Plan, and was fully vested and exercisable on the grant date. Following this grant, he beneficially owns 250 derivative securities of this option class.
Modular Medical, Inc. director Philip Brent Sheibley received an option grant to purchase 250 shares of common stock on the company’s stock. The option has an exercise price of $4.55 per share, was granted under the company’s Outside Director Compensation Plan, and was fully vested and exercisable on the grant date.
Following the grant, Sheibley beneficially owns 250 options of this class of derivative security, according to the Form 4.
Modular Medical, Inc. director Steven G. Felsher reported compensation-related equity awards. He received an option to purchase 250 shares of common stock at an exercise price of $4.55 per share, fully vested and exercisable on the grant date, under the Outside Director Compensation Plan. He was also granted 25 shares of common stock with no purchase price. After this grant, he directly owns 8,473 shares of common stock. The reported share amounts reflect the impact of a 1-for-30 reverse stock split effective March 31, 2026.
DeSisto Duane M reported acquisition or exercise transactions in this Form 4 filing.
Modular Medical, Inc. director Duane M. DeSisto received a grant of 83 shares of common stock on March 31, 2026 as compensation under the company’s Outside Director Compensation Plan. The grant was at no cash cost per share and brought his directly held stake to 8,544 shares.
A 1-for-30 reverse stock split of Modular Medical’s common stock, effective March 31, 2026, is reflected in the reported share amounts, meaning both the grant and total holdings are shown on a post-split basis.